Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells

Leukemia

Volumn 23, Issue 9, 2009, Pages 1557-1563

  Renouf, B ^a   Hollville, E ^a   Pujals, A ^a   Tetaud C ^a   Garibal, J ^a   Wiels, J ^a  

^a UMR 8126   (France)

Author keywords

Burkitt's lymphoma; EBV; Nutlin 3; P21 WAF1; P53

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ETOPOSIDE; IMIDAZOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUTLIN 3; PIPERAZINE DERIVATIVE; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; EPSTEIN BARR VIRUS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HERPESVIRUS 4, HUMAN; HUMANS; IMIDAZOLES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349326111     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.92     Document Type: Article

References (50)

1. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-2908.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
3. Vousden KH, Lu X. Live or let die: the cell0s response to p53. Nat Rev Cancer 2002; 2: 594-604.
4. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003; 1: 993-1000.
5. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005; 5: 3-8.
6. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
7. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
8. Capoulade C, Bressac-de Paillerets B, Lefrere I, Ronsin M, Feunteun J, Tursz T et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt0s lymphoma cells. Oncogene 1998; 16: 1603-1610.
9. Landers JE, Cassel SL, George DL. Translational enhancement of MDM2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 1997; 57: 3562-3568.
10. Zhang R, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 2000; 6: 393-416.
11. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559.
12. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
13. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P et al. Reactivation of the p53 pathway as a treatment modality for KSHVinduced lymphomas. J Clin Invest 2007; 117: 1019-1028.
14. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al. Non-genotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609-3617.
15. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007; 26: 3473-3481.
16. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006; 5: 2358-2365.
17. Cao C, Shinohara ET, Subhawong TK, Geng L, Woon Kim K, Albert JM et al. Radiosensitization of lung cancer by Nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 2006; 5: 411-417.
18. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109-4114.
19. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M et al. Inhibition of p53-murine double minute 2 interaction by Nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 2007; 13: 3380-3387.
20. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 4122-4129.
21. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413-5417.
22. Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A et al. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt0s lymphoma in children. Leukemia 2004; 18: 584-588.
23. Lindstrom MS, Klangby U, Wiman KG. p14 ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001; 20: 2171-2177.
24. Lindstrom MS, Wiman KG. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 2002; 12: 381-387.
25. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994; 84: 2412-2421.
26. Capoulade C, Mir LM, Carlier K, Lecluse Y, Tetaud C, Mishal Z et al. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both MDM2 and p53 antisense oligodeoxynucleotides. Blood 2001; 97: 1043-1049.
27. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803-821.
28. Rowe M, Rowe DT, Gregory CD, Young LS, Farrel PJ, Rupani H et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt0s lymphoma cells. EMBO J 1987; 6: 2743-2751.
29. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci USA 2006; 103: 14935-14940.
30. O'Nions J, Allday MJ. Epstein-Barr virus can inhibit genotoxininduced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 2003; 22: 7181-7191.
31. Wade M, Allday MJ. Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol 2000; 20: 1344-1360.
32. Okan I, Wang Y, Chen F, Hu LF, Imreh S, Klein G et al. The EBVencoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 1995; 11: 1027-1031.
33. Lenoir GM, Preudohomme JL, Bernheim A, Berger R. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt0s lymphoma. Nature 1982; 298: 474-476.
34. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 1999; 96: 14517-14522.
35. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639-649.
36. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007; 10: 13-29.
37. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13: 23-31.
38. Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi0s sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol 2007; 81: 1912-1922.
39. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27: 997-1003.
40. Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K et al. MDM2 antagonist Nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 2009; 15: 933-942.
41. Ablashi DV, Chatlynne LG, Whitman Jr JE, Cesarman E. Spectrum of Kaposi0s sarcoma-associated herpesvirus, or human herpesvirus 8. diseases. Clin Microbiol Rev 2002; 15: 439-464.
42. Jiang M, Pabla N, Murphy RF, Yang T, Yin XM, Degenhardt K et al. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem 2007; 282: 2636-2645.
43. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005; 65: 1918-1924.
44. Kranz D, Dobbelstein M. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res 2006; 66: 10274-10280.
45. Prabhu NS, Somasundaram K, Tian H, Enders GH, Satyamoorthy K, Herlyn M et al. The administration schedule of cyclindependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity. Int J Oncol 1999; 15: 209-216.
46. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. Cooperative effects of genes controlling the G2/M checkpoint. Genes Dev 2000; 14: 1584-1588.
47. Lu Y, Tatsuka M, Takebe H, Yagi T. Involvement of cyclindependent kinases in doxorubicin-induced apoptosis in human tumor cells. Mol Carcinog 2000; 29: 1-7.
48. Lin CS, Kuo HH, Chen JY, Yang CS, Wang WB. Epstein-Barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post-translationally. J Mol Biol 2000; 303: 7-23.
49. Allday MJ, Inman GJ, Crawford DH, Farrell PJ. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J 1995; 14: 4994-5005.
50. O'Nions J, Turner A, Craig R, Allday MJ. Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53. J Virol 2006; 80: 12408-12413.